Ardsley Advisory Partners LP Acquires Shares of 50,000 Humana Inc. $HUM

Ardsley Advisory Partners LP bought a new position in shares of Humana Inc. (NYSE:HUM) in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 50,000 shares of the insurance provider’s stock, valued at approximately $12,224,000. Humana accounts for approximately 1.6% of Ardsley Advisory Partners LP’s holdings, making the stock its 13th biggest position.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Humana by 16.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,136,538 shares of the insurance provider’s stock worth $300,728,000 after purchasing an additional 158,528 shares during the period. Focus Partners Wealth increased its holdings in shares of Humana by 104.2% during the 1st quarter. Focus Partners Wealth now owns 6,429 shares of the insurance provider’s stock worth $1,701,000 after buying an additional 3,281 shares during the last quarter. Swedbank AB raised its position in shares of Humana by 5.3% during the 2nd quarter. Swedbank AB now owns 100,397 shares of the insurance provider’s stock valued at $24,545,000 after buying an additional 5,032 shares during the period. Circle Wealth Management LLC acquired a new position in Humana in the first quarter valued at approximately $425,000. Finally, Kera Capital Partners Inc. purchased a new position in Humana in the second quarter worth approximately $253,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Price Performance

HUM stock opened at $250.04 on Wednesday. The business’s 50-day moving average is $262.35 and its two-hundred day moving average is $257.72. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.02 and a quick ratio of 2.02. The firm has a market capitalization of $30.07 billion, a P/E ratio of 23.43, a P/E/G ratio of 1.50 and a beta of 0.46. Humana Inc. has a 1 year low of $206.87 and a 1 year high of $315.35.

Humana (NYSE:HUM) last released its earnings results on Wednesday, November 5th. The insurance provider reported $3.24 earnings per share for the quarter, topping analysts’ consensus estimates of $2.95 by $0.29. The firm had revenue of $32.65 billion for the quarter, compared to analyst estimates of $31.99 billion. Humana had a net margin of 1.02% and a return on equity of 12.86%. The business’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $4.16 earnings per share. Analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Friday, December 26th will be given a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a dividend yield of 1.4%. The ex-dividend date of this dividend is Friday, December 26th. Humana’s payout ratio is 33.18%.

Analysts Set New Price Targets

HUM has been the topic of a number of research analyst reports. Truist Financial reduced their target price on Humana from $300.00 to $285.00 and set a “hold” rating on the stock in a research report on Monday, November 10th. Weiss Ratings reissued a “sell (d+)” rating on shares of Humana in a research report on Wednesday, October 8th. Sanford C. Bernstein boosted their price objective on shares of Humana from $269.00 to $341.00 and gave the company an “outperform” rating in a report on Friday, September 5th. Mizuho upped their target price on shares of Humana from $300.00 to $345.00 and gave the company an “outperform” rating in a research report on Thursday, October 9th. Finally, Guggenheim reiterated a “buy” rating on shares of Humana in a research report on Friday, October 3rd. Nine equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Humana has a consensus rating of “Hold” and an average price target of $296.84.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.